ALNY
Alnylam Pharmaceuticals, Inc. NASDAQ$296.11
Mkt Cap $39.9B
52w Low $245.96
20.1% of range
52w High $495.55
50d MA $320.98
200d MA $393.04
P/E (TTM)
123.9x
EV/EBITDA
92.8x
P/B
49.1x
Debt/Equity
1.6x
ROE
39.8%
P/FCF
111.9x
RSI (14)
—
ATR (14)
—
Beta
0.38
50d MA
$320.98
200d MA
$393.04
Avg Volume
1.2M
About
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | 0.90 | 1.51 | +68.7% | 301.19 | +2.1% | +2.8% | -1.7% | — | — | — | — | — |
| Feb 12, 2026 | BMO | 1.16 | 0.82 | -29.3% | 322.28 | -2.4% | -4.3% | -2.4% | +3.2% | +3.2% | +5.3% | -1.0% | — |
| Oct 30, 2025 | BMO | 0.56 | 2.90 | +416.9% | 481.59 | -6.6% | -6.7% | -5.3% | -9.9% | -12.1% | -9.8% | -5.6% | — |
| Jul 31, 2025 | BMO | -0.54 | 0.32 | +158.9% | 339.80 | +3.0% | +15.4% | +18.2% | +23.5% | +23.3% | +26.0% | +31.5% | — |
| May 1, 2025 | BMO | -0.89 | -0.01 | +98.9% | 263.24 | -2.3% | -3.1% | -1.5% | +3.9% | +2.5% | +5.1% | +16.3% | — |
| Feb 13, 2025 | BMO | -0.62 | 0.06 | +109.7% | 265.96 | -2.8% | -0.4% | -3.6% | -6.0% | -5.8% | -5.6% | -4.8% | — |
| Oct 31, 2024 | BMO | -0.92 | -0.50 | +45.4% | 281.49 | -2.2% | -5.3% | -2.7% | -4.1% | -5.8% | -3.0% | -10.1% | — |
| Aug 1, 2024 | BMO | -1.07 | 0.56 | +152.3% | 237.46 | +5.3% | +13.1% | +14.6% | +11.6% | +10.6% | +9.6% | +6.9% | — |
| May 2, 2024 | BMO | -1.12 | -0.16 | +85.7% | 149.96 | +0.6% | +0.2% | +1.6% | +0.8% | +2.9% | +1.6% | +0.3% | — |
| Feb 15, 2024 | BMO | -1.20 | -1.10 | +8.3% | 164.15 | -8.6% | -10.2% | -10.4% | -8.8% | -5.7% | -0.8% | -10.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | RBC Capital | Maintains | Outperform → Outperform | — | $309.49 | $308.76 | -0.2% | -4.3% | — | — | — | — |
| May 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $309.49 | $308.76 | -0.2% | -4.3% | — | — | — | — |
| Apr 13 | Truist | Maintains | Buy → Buy | — | $322.11 | $320.66 | -0.5% | +3.4% | +5.4% | +3.5% | -0.6% | -3.9% |
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $308.05 | $313.34 | +1.7% | +6.7% | +6.5% | +3.0% | +2.6% | +7.4% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $308.05 | $313.34 | +1.7% | +6.7% | +6.5% | +3.0% | +2.6% | +7.4% |
| Mar 16 | Jefferies | Downgrade | Buy → Hold | — | $313.41 | $311.22 | -0.7% | +1.8% | +2.2% | +0.4% | -0.7% | -0.4% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $332.61 | $328.86 | -1.1% | +0.0% | +2.0% | +1.1% | -1.0% | +0.1% |
| Feb 17 | Freedom Broker | Upgrade | Hold → Buy | — | $314.40 | $316.80 | +0.8% | +5.8% | +5.8% | +7.9% | +6.9% | +4.8% |
| Feb 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $314.40 | $316.80 | +0.8% | +5.8% | +5.8% | +7.9% | +6.9% | +4.8% |
| Feb 17 | Freedom Capital Markets | Upgrade | Hold → Buy | — | $314.40 | $316.80 | +0.8% | +5.8% | +5.8% | +7.9% | +6.9% | +4.8% |
Recent Filings
8-K
Alnylam Pharmaceuticals, Inc. -- 8-K Filing
Alnylam surpassed $1 billion in quarterly product revenues for the first time, driven by AMVUTTRA's launch for ATTR-CM, signaling strong commercial momentum for the RNAi therapeutics leader.
Apr 30
8-K
Unknown — 8-K Filing
Tenaya Therapeutics (TNYA) is advancing its cardiac disease pipeline with positive momentum, suggesting potential near-term clinical catalysts that could justify its clinical-stage valuation if development programs succeed.
Mar 11
8-K · 1.01
!! High
Tenaya Therapeutics, Inc. -- 8-K 1.01: Collaboration Agreement
Tenaya Therapeutics secured a $10 million collaboration agreement with Alnylam Pharmaceuticals to develop RNA-based therapeutics, providing funding and potential revenue expansion for the smaller biotech firm.
Mar 5
8-K · 5.02
!!! Very High
Alnylam Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Alnylam's board granted a special equity award to new CEO Yvonne Greenstreet as part of her executive compensation package, effective March 2, 2026.
Mar 4
8-K
Alnylam Pharmaceuticals, Inc. -- 8-K Filing
Alnylam Pharmaceuticals advanced its RNAi pipeline with three new Phase 3 studies, four proprietary CTAs, and a novel manufacturing platform, positioning the company for sustained growth in genetic disease treatment.
Feb 12
Data updated apr 24, 2026 5:26pm
· Source: massive.com